<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; AIMS: Liver X receptors (LXR) are transcriptional regulators of cholesterol metabolism, controlling cholesterol flow into cells, catabolism, and efflux </plain></SENT>
<SENT sid="1" pm="."><plain>Cholesterol controls cell proliferation; disruptions in cholesterol metabolism have been associated with development of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated whether expression of activated LXR protects against intestinal <z:mp ids='MP_0002006'>tumorigenesis</z:mp> in mice </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We analyzed development of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> in mice that express a constitutive active form of LXRa only in the intestinal epithelium, under the control of villin promoter (iVP16LXRa) </plain></SENT>
<SENT sid="4" pm="."><plain>These mice were crossed with Apc (min/+) mice, or given azoxymethane followed by <z:chebi fb="0" ids="52071">dextran</z:chebi> <z:chebi fb="0" ids="32149">sodium sulfate</z:chebi> (DSS), to assess <z:e sem="disease" ids="C0021841" disease_type="Neoplastic Process" abbrv="">intestinal tumor</z:e> formation </plain></SENT>
<SENT sid="5" pm="."><plain>We also assessed proliferation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of a human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell line (HT29) transfected with an adenoviral vector that expressed Ad VP16hLXRa, compared with cells expressing AdVP16 (control), and their ability to form xenograft <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in mice </plain></SENT>
<SENT sid="6" pm="."><plain>HT29 cells were also incubated with the LXR ligand GW3965 </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: In human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells, ligand-induced activation of LXR or transfection with Ad VP16hLXRa blocked G1 phase, increased caspase-dependent <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and slowed growth of xenograft <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in mice </plain></SENT>
<SENT sid="8" pm="."><plain>iVP16LXRa mice formed fewer, smaller <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> than <z:chebi fb="0" ids="4911">VP16</z:chebi> (control) mice following administration of azoxymethane and DSS </plain></SENT>
<SENT sid="9" pm="."><plain>APC (min/+)/iVP16LXRa mice also developed fewer, smaller <z:e sem="disease" ids="C0021841" disease_type="Neoplastic Process" abbrv="">intestinal tumors</z:e> than APCmin/+/iVP16 mice </plain></SENT>
<SENT sid="10" pm="."><plain>Gene expression analysis indicated that activation of LXRa affected <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolic networks and <z:mp ids='MP_0003192'>increased cholesterol efflux</z:mp> in the intestine </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Expression of activated LXRa blocks proliferation of human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells and slows growth of xenograft <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in mice </plain></SENT>
<SENT sid="12" pm="."><plain>It also reduces <z:e sem="disease" ids="C0021841" disease_type="Neoplastic Process" abbrv="">intestinal tumor</z:e> formation following administration of chemical carcinogens, and in Apc (min/+) mice </plain></SENT>
<SENT sid="13" pm="."><plain>LXR <z:chebi fb="4" ids="48705">agonists</z:chebi> might therefore be developed as therapeutics for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>